DexCom, Inc. $DXCM Stock Position Boosted by National Pension Service

National Pension Service boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 10.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 618,615 shares of the medical device company’s stock after buying an additional 58,262 shares during the period. National Pension Service’s holdings in DexCom were worth $41,057,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CVA Family Office LLC grew its position in DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after buying an additional 147 shares in the last quarter. ORG Partners LLC boosted its position in shares of DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 281 shares in the last quarter. Spire Wealth Management boosted its position in shares of DexCom by 113.8% during the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after purchasing an additional 305 shares in the last quarter. Aventura Private Wealth LLC bought a new position in shares of DexCom during the 4th quarter valued at about $43,000. Finally, Rothschild Investment LLC boosted its position in shares of DexCom by 59.9% during the 3rd quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock valued at $44,000 after purchasing an additional 245 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM opened at $73.74 on Monday. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The company has a 50-day moving average of $64.17 and a two-hundred day moving average of $66.53. The stock has a market cap of $28.45 billion, a price-to-earnings ratio of 31.51, a PEG ratio of 1.22 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the company posted $0.32 earnings per share. The business’s revenue for the quarter was up 15.0% on a year-over-year basis. On average, equities research analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Raymond James Financial set a $81.00 price objective on shares of DexCom in a research report on Friday, May 1st. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Evercore upgraded shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective for the company in a research report on Tuesday, March 24th. Piper Sandler restated an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Finally, Wells Fargo & Company reduced their price objective on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research report on Friday, February 13th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $82.42.

Insiders Place Their Bets

In other news, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the sale, the insider directly owned 382,482 shares of the company’s stock, valued at $27,538,704. This represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the sale, the director owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 32,871 shares of company stock worth $2,306,638 over the last ninety days. 0.28% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.